Seres Therapeutics (MCRB) Misses Q4 EPS by 61c

Seres Therapeutics (NASDAQ: MCRB) reported Q4 EPS of ($0.81), $0.61 worse than the analyst estimate of ($0.20).

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• JPMorgan Reiterates Overweight Rating on Samsung Electronics Co Ltd. (005930:KS) (SSNLF)
• Canaccord Starts L1 Group Ltd (L1G:AU) at Buy
• Anthropic delays planned IPO from October to November - WSJ